Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development

Clinical and Applied Thrombosis/Hemostasis

Volumn 4, Issue 4, 1998, Pages 227-237

  Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulant; Antithrombin agents; Antithrombotic

Indexed keywords

ACTIVATED PROTEIN C; ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; BAZOTROXOBIN; DESMOPRESSIN; DESULFATOHIRUDIN; DEXTRO PHENYLALANYLPROLYLARGININAL; EFEGATRAN; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; KALLIKREIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NAPSAGATRAN; TERT BUTYLOXYCARBONYL DEXTRO PHENYLALANYLPROLYLARGININAL; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031704568     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969800400403     Document Type: Article

References (76)

1. De Fouw NJ, van Hinsberg VW, de Jong YF, et al. The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost 1987;57:176.
2. Collen D, Lijnen HR, Todd PA, Goa KL. Tissue-type plasminogen activator: a review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 1989;38:346.
3. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989;74:222.
4. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1989;67:1215.
5. Hoylaerts M, Rijken HR, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator, role of fibrin. J Biol Chem 1982;257:2912.
6. Coleman RW. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 1968;35:273.
7. Goldsmith GH, Saito H, Ratnoff OD. The activation of plasminogen by Hageman factor fragments. J Clin Invest 1978;62:54.
8. Sakata Y, Curriden S, Lawrence D, et al. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985; 82:1121.
9. Barabas E, Szell E, Bajusz S. Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors. Blood Coag Fibrinolys 1993;4:243.
10. Callas D, Bacher P, Iqbal O, et al. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res 1994;73(3):193.
11. Gilboa N, Villanuueva, Fenton JW II. Inhibition of fibrinolytic enzymes by thrombin inhibitors. Enzyme 1988;40:144.
12. Petersen TE, Roberts HR, Sottrup-Jensen L, Magnusson S. Primary structure of hirudin, a thrombin-specific inhibitor. In: Peters H, ed. Peptides of the Biological Fluids. Oxford: Pergamon, 1976:145.
13. Callas D, Fareed J. Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. Thromb Res 1996;83:463.
14. Dodt J, Kohler S, Schmitz T, et al. Distinct binding sites of Ala 48-hirudin 1-47 and Ala 48-hirudin 48-65 on α thrombin. J Biol Chem 1990;265:713.
15. Fareed J, Callas D, Hoppensteadt D, et al. Recent developments in antithrombotic agents. Exp Opin Invest Drugs 1995;4(5):389.
16. Harvey RP, Degryse E, Stefani L, et al. Cloning and expression of cDNA coding for the anticoagulant hirudin from the bloodsucking leech Hirudo medicinalis. Proc Natl Acad Sci USA 1986;83:1084.
17. Scharf M, Engels J, Triplier D. Primary structures of new "isohirudins." FEBS Lett 1989;225:105.
18. Zawilska K, Zozulinska M, Turowiecka Z. et al. The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits. Thromb Res 1993;69(3):315.
19. DiMaio J, Gibbs B, Minon D, et al. Bifunctional thrombin inhibitors based on the sequence of hirudin. J Biol Chem 1990;265(35): 21698.
20. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095.
21. Cannon CP, Maraganore JM, Loscalzo J. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993;71:778.
22. Theroux P, Lidon R. Anticoagulants and their use in acute ischemic syndromes. In: Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia: WB Saunders Co., 1994:23.
23. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87(5):1622.
24. Vlasuk G, Vallar PL, Weinhouse MI, et al. A novel inhibitor of thrombin containing multiple recognition sequences linked by α-keto amide transition state. Circulation 1994;90(4, Part 2):1-348.
25. Hijikata-Okunomiya A, Okamoto S. A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost 1992;18(1):135.
26. Gibbs CS, Coutre SE, Tsiang M, et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature 1995;378:413.
27. Maruyama I. Synthetic anticoagulants. Jpn J Clin Hematol 1990; 31:776.
28. Tamao Y, Yamamoto T, Hirata T, et al. Effect of argipidine (MD-805) on blood coagulation. Jpn Pharmacol Ther 1986;14:869.
29. Tamao Y, Yamamoto T, Kimamoto R, et al. Effect of a selective thrombin-inhibitor MCI-9038 on fibrinolysis in vitro and in vivo Thromb Haemost 1986;562:28.
30. Matsuo T, Kario K, Kodama K, Okamoto S. Clinical applications of the synthetic thrombin inhibitor. Argatroban (MD-805). Semin Thromb Hemost 1992;18(2):155.
31. Oshiro T, Kanbayashi J, Kosaki G. Antithrombotic therapy of patient with peripheral arterial reconstruction-clinical study on MD805. Blood Vessels 1983;14:216.
32. Yonekawa Y, Handa H, Okamoto S, et al. Treatment of cerebral infarction in the acute stage with synthetic antithrombin MD805: Clinical study among multiple institutions. Arch Jpn Chir 1986; 55:711.
33. Fareed J, Messrnore HL, Kindel G, Balis JU. Inhibition of serine proteases by low molecular weight peptides and their derivatives. NY Acad Sci 1981;370:765.
34. Bajusz S, Barabás E, Sźell E, Bagdy D. Peptide aldehyde inhibitors of the fibrinogen-thrombin reaciton. In: Meienhofer J. ed. Peptides - Chemistry. Structure and Biology. Ann Arbor. MI: Ann Arbor Science Publications. Inc., 1975:603.
35. Bajusz S, Barabás E, Tolnay P, et al. Inhibition of thrombin and trypsin by tripeptide aldehydes. Int J Peptide Protein Res 1978; 12:217.
36. 4. Throm Haemost 1992;67(3):325.
37. Bajusz S, Széll E, Bagdy D, et al. US Patent No. 4,703,036, 1987.
38. Bajusz S, Széll E, Bagdy D, et al. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 1990;33:1729.
39. Kettner C, Shaw E. The selective inactivation of thrombin by peptides of chloromethyl ketone. In: Lundblad RL, Fenton JW, Mann KG, eds. Chemistry and Biology of Thrombin. Ann Arbor, Ml: Ann Arbor Science, 1977:129.
40. Stuber W, Kosina H, Heimburger N. Synthesis of a tripeptide with a C-terminal moiety and the inhibition of proteinases. Int J Peptide Protein Res 1988;31:63.
41. 3 (MDL73756). Thromb Haemost 1991;65:1290.
42. Cheng I, Scully MF, Goodwin CA, et al. Peptide α-amino-phosphonic acids. A new type of thrombin inhibitors. Thromb Haemost 1991;65:1289.
43. Kettner C, Mesinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990;265: 18289.
44. Tapparelli C, Metternich R, Ehrhardt C, et al. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J Biol Chem 1993;268(7):4734.
45. Bock LC, Griffin LC, Latham JA, et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992;355(6360):564.
46. Macaya RF, Schultze P, Smith FW, et al. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci USA 1993;90:3745.
47. Paborsky LR, McCurdy SN, Griffin LC, et al. The single-stranded DNA aptamer binding-site of human thrombin. J Biol Chem 1993; 268:20808.
48. Li WX, Kaplan AV, Grant GW, et al. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood 1994;83(3):677.
49. Latham JA, Johnson R, Toole JJ. The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(I-pentynyl)-2′-deoxyuridine. Nucleic Acids Res 22:2817-2822, 1994.
50. Antman EM. for the TIMI 9A Investigators Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1995;90:1624.
51. Antman EM. Antiplatelet/antithrombotic agents. Presented at the Plenary Seminar, Joint AHA/European Society of Cardiology Symposium: Contemporary Strategies for Acute Myocardial Infarction. American Heart Association, 68th Scientific Sessions, Anaheim, California, November 1995, unpublished.
52. Hermann JR, Kutryk MJ, Serruys PW. Clinical trials of direct thrombin inhibitors during invasive procedures. Thromb Haemost 1997;78(1):367.
53. Verstraete M. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997;78(1): 357.
54. White HD. Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes. Thromb Haemost 1997;78( 1):364.
55. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631.
56. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)IIa Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775.
57. Investigators of the OASIS trial. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation. Circulation 1997;96:769.
58. White HD, Aylward PE, Frey M, et al. A randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155.
59. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039.
60. Vermeer F, Vahanian A, Fels PW, et al. Intravenous argatroban versus heparin as co-medication to alteplasein the treatment of acute myocardial infarction: preliminary results of the ARGAMI pilot study. J Am Coll Cardiol 1997;29:185.
61. Herrman PR, Suryapranata H, den Heijer P, et al. Argatroban during percutaneous transluminal angioplasty; results of a dose verification study. J Thromb Thrombolysis 1996;3:367.
62. Lewis B, Grassman E, Johnson S, et al. Pilot study of argatroban in patients with heparin allergy [Abstract]. In Abstracts from the 69th Scientific Sessions of the American Heart Association, New Orleans, 1996:1233.
63. Eriksson BI, Ekman S, Kalebo P, et al: Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin. CGP 39393. Lancet 1996;347:635.
64. Eriksson BI. Recombinant hirudin, desirudin (REVASC®) for prophylaxis of thromboembolic complications in patients undergoing total hip replacement. Presented at the Fourteenth International Congress of Thrombosis, 1996; Montpellier.
65. Ginsberg JS, Nurmohamed MT, Gent M, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994;90:2385.
66. Bounamex H, Ehringer H, Hulting J, et al. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (Napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis. Thromb Haemost 1997;78:997.
67. Fareed J, Walenga JM, Iyer L, et al. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent. Blood Coag Fibrinolys 1991;2:135.
68. Bruggener E, Walsmann P, Markwardt F. Neutralization of hirudin anticoagulant action by DIP-thrombin. Parmazie 1989;44:648.
69. Butler KD, Dolan SL, Talbot MD, et al. Factor VIII and DDAVP reverse the effect of recombinant desulfatohirudin (CGP-39393) on bleeding in the rat. Blood Coag Fibrinolys 1993;4:459.
70. Diehl KH, Romisch B, Hein B, et al. Potential hirudin antidote: investigation of an activated prothrombin complex concentrate in animal models. In Annals of Hematology: Proceedings of the 3rd Annual Meeting in Munich, February 16-19, 1994. The German Society of Thrombosis and Hemostasis 68(II):A86.
71. Fuster V, Verstraete M. Thrombosis in Cardiovascular Disorders. Philadelphia: WB Saunders & Co., 1992.
72. Irani MS, White HJ, Sexton RN. Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. Am J Cardiol 1995;75:422.
73. Kaiser B, Callas D, Hoppensteadt D, et al. Comparative studies on the inhibitory spectrum of recombinant hirudin. DuP 714 and heparin on the generation of thrombin and factor Xa generation in biochemically defined systems. Thromb Res 1994;73(5):327.
74. Kaiser B, Fareed J, Hoppensteadt D, et al. Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems. Thromb Res 1992;65:157.
75. Nowak G, Bucha E. Ecarin-induccd prothrombin intermediate formation: an effective antidote principle to antagonize toxic levels of hirudin. Presented at the 5th Annual Symposium on Advances in Anticoagulant, Antithrombiotic and Thrombolytic Therapeutics; Boston, October 24-25, 1994; Boston.
76. Iqbal O, Fareed J, Steuver T, et al. Protein C depleted activated prothrombin complex neutralizes the bleeding associated with recombinant hirudin. Blood 1994;84:769.